Validation of a Deep Learning Tool for Opportunistic Osteoporosis Screening Using Routine Non-Contrast CT Scans
2026年9月1日 更新者:Yang Fan、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Prospective Clinical Validation Study of a Deep Learning Model for Opportunistic Osteoporosis Screening Based on Non-Contrast CT Scans
The goal of this clinical trial is to test if an artificial intelligence (AI) tool called DeepBMD can accurately identify people at high risk for osteoporosis using routine chest or abdomen CT scans. The main questions it aims to answer are:
- Can the DeepBMD tool correctly identify people who have osteoporosis compared to the standard bone density test, dual-energy X-ray absorptiometry (DXA)?
- Is it practical to use this AI tool in real-world hospital settings to find and contact high-risk patients? Researchers will use the DeepBMD tool to analyze existing CT scans. If the tool flags a patient as high risk, researchers will call them to invite them for a standard bone density test (DXA).
Participants will:
- Have their existing chest or abdomen CT scan analyzed by the DeepBMD AI tool;
- Receive a phone call from the research team if identified as high risk;
- Visit the clinic for a free standard bone density test (DXA) if they agree to participate.
研究概览
研究类型
观察性的
注册 (估计的)
100
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
取样方法
非概率样本
研究人群
Patients who underwent non-contrast CT at our hospital (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) and were identified as high-risk for osteoporosis by the DeepBMD model.
描述
Inclusion Criteria:
- Underwent non-contrast CT at our institution, with qualified image quality and no severe artifacts;
- Identified as high-risk for osteoporosis by the DeepBMD model;
- Had valid contact information available in the PACS, possessed normal cognitive and communication abilities, and was able to cooperate with telephone follow-ups and on-site examinations;
- Voluntarily participated in the study, was able to sign a written informed consent form on-site, and agreed to undergo DXA examination.
Exclusion Criteria:
- Severe spinal deformity, postoperative spinal internal fixation, malignant bone metastasis, or severe osteolytic lesions that may interfere with measurements;
- A confirmed diagnosis of osteoporosis with ongoing standardized treatment;
- Inability to be contacted, explicit refusal of follow-up, or inability to visit the hospital for informed consent signing and DXA examination.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
High-risk patients for osteoporosis identified by DeepBMD model
Patients who underwent routine chest or abdominal CT scans and were identified as high risk for osteoporosis by the DeepBMD AI model.
These participants will be contacted via telephone, invited to the clinic, and undergo a free DXA scan to verify bone mineral density.
|
The DeepBMD model is applied to routine chest or abdominal CT scans to identify patients at high risk for osteoporosis.
This is a non-invasive image analysis used solely for screening and recruitment purposes, not as a therapeutic intervention.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Diagnostic performance of DeepBMD model for osteoporosis screening
大体时间:Concurrent with the DXA validation visit following the CT analysis (within 7 days).
|
The diagnostic performance of the DeepBMD model will be evaluated by comparing its predictions against the gold standard Dual-energy X-ray Absorptiometry (DXA).
Specifically, we will calculate the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and the Area Under the Receiver Operating Characteristic Curve (AUC) for identifying patients with osteoporosis.
|
Concurrent with the DXA validation visit following the CT analysis (within 7 days).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Feasibility of the DeepBMD screening and recall workflow
大体时间:At the end of recruitment
|
It will be assessed by calculating the proportion of patients identified as high-risk by DeepBMD who successfully complete the telephone follow-up and undergo the confirmatory DXA scan within the scheduled timeframe.
We will also record the reasons for refusal or loss to follow-up to evaluate the acceptability of this AI-driven screening pathway.
|
At the end of recruitment
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Fan Yang, PhD, MD、Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Jang S, Graffy PM, Ziemlewicz TJ, Lee SJ, Summers RM, Pickhardt PJ. Opportunistic Osteoporosis Screening at Routine Abdominal and Thoracic CT: Normative L1 Trabecular Attenuation Values in More than 20 000 Adults. Radiology. 2019 May;291(2):360-367. doi: 10.1148/radiol.2019181648. Epub 2019 Mar 26.
- Wang P, She W, Mao Z, Zhou X, Li Y, Niu J, Jiang M, Huang G. Use of routine computed tomography scans for detecting osteoporosis in thoracolumbar vertebral bodies. Skeletal Radiol. 2021 Feb;50(2):371-379. doi: 10.1007/s00256-020-03573-y. Epub 2020 Aug 7.
- Smith AD. Screening of Bone Density at CT: An Overlooked Opportunity. Radiology. 2019 May;291(2):368-369. doi: 10.1148/radiol.2019190434. Epub 2019 Mar 26. No abstract available.
- Zeng Q, Li N, Wang Q, Feng J, Sun D, Zhang Q, Huang J, Wen Q, Hu R, Wang L, Ma Y, Fu X, Dong S, Cheng X. The Prevalence of Osteoporosis in China, a Nationwide, Multicenter DXA Survey. J Bone Miner Res. 2019 Oct;34(10):1789-1797. doi: 10.1002/jbmr.3757. Epub 2019 Aug 29.
- Cheng X, Zhao K, Zha X, Du X, Li Y, Chen S, Wu Y, Li S, Lu Y, Zhang Y, Xiao X, Li Y, Ma X, Gong X, Chen W, Yang Y, Jiao J, Chen B, Lv Y, Gao J, Hong G, Pan Y, Yan Y, Qi H, Ran L, Zhai J, Wang L, Li K, Fu H, Wu J, Liu S, Blake GM, Pickhardt PJ, Ma Y, Fu X, Dong S, Zeng Q, Guo Z, Hind K, Engelke K, Tian W; China Health Big Data (China Biobank) project investigators. Opportunistic Screening Using Low-Dose CT and the Prevalence of Osteoporosis in China: A Nationwide, Multicenter Study. J Bone Miner Res. 2021 Mar;36(3):427-435. doi: 10.1002/jbmr.4187. Epub 2020 Nov 4.
- Lin X, Xiong D, Peng YQ, Sheng ZF, Wu XY, Wu XP, Wu F, Yuan LQ, Liao EY. Epidemiology and management of osteoporosis in the People's Republic of China: current perspectives. Clin Interv Aging. 2015 Jun 25;10:1017-33. doi: 10.2147/CIA.S54613. eCollection 2015.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年7月28日
初级完成 (实际的)
2026年8月28日
研究完成 (估计的)
2026年9月1日
研究注册日期
首次提交
2026年7月22日
首先提交符合 QC 标准的
2026年7月27日
首次发布 (实际的)
2026年7月31日
研究记录更新
最后更新发布 (实际的)
2026年9月3日
上次提交的符合 QC 标准的更新
2026年9月1日
最后验证
2026年9月1日
更多信息
与本研究相关的术语
关键字
其他研究编号
- UHCT260668
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
是的
IPD 计划说明
De-identified individual participant data (IPD) will be made available to researchers who provide a methodologically sound proposal.
The shared data will include the demographic information, DeepBMD screening results, and confirmatory DXA T-scores used in the study analyses.
Requests should be directed to the corresponding author via email.
Data will be available for non-commercial academic research purposes only.
Applicants must sign a data access agreement prior to receiving the data.
IPD 共享时间框架
Data will be available beginning 3 months following article publication and ending 36 months following article publication.
IPD 共享访问标准
Researchers who provide a methodologically sound proposal for specific research questions related to osteoporosis screening or AI diagnostics will be granted access.
Approved researchers will have access to the de-identified dataset containing patient demographics, imaging analysis results, and clinical outcomes.
Access will be granted via secure email transfer after signing a data use agreement.
IPD 共享支持信息类型
- 研究方案
- 树液
- 分析代码
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.